Valence 로고
인기
로그인

관심목록에 추가

Bright Minds Biosciences ...

NasdaqCM: DRUG · 실시간 가격 · USD
84.04
+4.56 (5.74%)
종가 기준: Aug 18, 2026, 3:59 PM

Bright Minds Biosciences Inc. (DRUG) Stock Price, Analysis & Data

5.74%
매수호가78.65
시가총액824.61M
매출 (ttm)n/a
순이익 (ttm)-24.51M
베타0.09
EPS (ttm)-2.15
P/E (ttm)n/a
선행 P/E-13.08
P/B (ttm)3.72
P/S (ttm)n/a
Earnings DateDec 22, 2026
매도호가80.03
거래량127,689
평균 거래량 (20일)309,995
시가79.48
전일 종가79.48
일중 범위78.72 - 84.42
52주 범위38.00 - 123.75
애널리스트Strong Buy
목표주가144.94 (72.47%)
배당n/a
배당락일n/a

DRUG 소개

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathi...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Mar 22, 2021
직원 수 26
상장 거래소 NasdaqCM
티커 DRUG
웹사이트 https://brightmindsbio.com
전체 기업 정보

재무 실적

2025년 Bright Minds Biosciences의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -12.23M로, 336.46% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 3명의 투자의견을 종합하면 DRUG 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 144.94로, 최근 주가 대비 72.47% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Bright Minds Biosciences가 Aug 14, 2026에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -0.24 예상치 상회 1.40, 및 67.57% 전년 대비 성장.

    • 다음 실적 발표

    Bright Minds Biosciences Inc.의 실적 발표 예정일은 Dec 22, 2026, 정규장 중입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1주 전 · Zacks

    Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

    The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ag...

    news image

    3주 전 · Zacks

    Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

    The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward tren...

    news image

    3주 전 · Zacks

    All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy

    Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

    news image

    2개월 전 · Motley Fool

    Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

    Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

    news image

    4개월 전 · Insider Monkey

    What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?

    Bright Minds Biosciences Inc (NASDAQ:DRUG) is among the best psychedelic stocks to buy in 2026. The company has multiple psychedelic drug candidates, including potential medicines for epilepsy. Its fl...

    2 페이지 중 1